Paul Chaplin, the chief executive officer of Bavarian Nordic A/S, is to step down from the vaccine company in an agreement with the board of directors. Mr Chaplin, who is leaving for personal reasons, will remain in his role for the remainder of 2026, or until a successor has been identified. Joining Bavarian Nordic in 1999, Mr Chaplin was appointed CEO in 2014. He led the development of the company’s smallpox and mpox vaccine. During his tenure, Bavarian Nordic grew from a small research-based company with a single government customer to a large vaccine manufacturer, made possible by acquisition of travel vaccines, tech transfer capability and commercial transformation.
Bavarian Nordic made the announcement on 2 March 2026.
Copyright 2026 Evernow Publishing Ltd.